{"id":"r-choep-14-with-12x-rituximab","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Nausea/vomiting"},{"rate":null,"effect":"Alopecia"},{"rate":null,"effect":"Infusion reactions"},{"rate":null,"effect":"Infection"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"CHOEP is a chemotherapy regimen that damages DNA and disrupts cell division in rapidly dividing lymphoma cells. Rituximab targets CD20 antigen on B-cell lymphomas, triggering antibody-dependent cellular cytotoxicity (ADCC) and direct apoptosis. The combination enhances tumor cell death through complementary mechanisms. The '14' refers to a 14-day cycle schedule.","oneSentence":"R-CHOEP 14 with rituximab combines chemotherapy (cyclophosphamide, doxorubicin, etoposide, prednisone) with the anti-CD20 monoclonal antibody rituximab to kill lymphoma cells through chemotoxicity and antibody-mediated immune destruction.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:31:10.738Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"High-grade non-Hodgkin's lymphoma"}]},"trialDetails":[{"nctId":"NCT00129090","phase":"PHASE3","title":"Mega-CHOEP: Conventional Chemo Vs HD Chemo Followed by Auto SCT in Younger Pts With Aggressive Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"German High-Grade Non-Hodgkin's Lymphoma Study Group","startDate":"2003-03","conditions":"Non-Hodgkin's Lymphoma (NHL)","enrollment":450}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["12 x Rituximab with 8 cycles of standard CHOEP-14"],"phase":"phase_3","status":"active","brandName":"R-CHOEP 14 with 12x Rituximab","genericName":"R-CHOEP 14 with 12x Rituximab","companyName":"German High-Grade Non-Hodgkin's Lymphoma Study Group","companyId":"german-high-grade-non-hodgkin-s-lymphoma-study-group","modality":"Small molecule","firstApprovalDate":"","aiSummary":"R-CHOEP 14 with rituximab combines chemotherapy (cyclophosphamide, doxorubicin, etoposide, prednisone) with the anti-CD20 monoclonal antibody rituximab to kill lymphoma cells through chemotoxicity and antibody-mediated immune destruction. Used for High-grade non-Hodgkin's lymphoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}